2 minute read
Bringing multimodal AI to healthcare
JIVA
Bringing multimodal AI to healthcare
The importance of AI across all industry sectors is now universally accepted. Organisations will apply AI technologies to transform business in ways not seen since the Industrial Revolution, fundamentally reinventing how they are run, compete and thrive. Implemented responsibly, AI will amplify human existence and improve how we live and work.
The AI market in totality is predicted to be worth $15.7 trillion by 2030. The opportunity is so great that the UK has created an AI Council to purposefully position the UK as a world leader in AI. However, AI has failed to address complex problems at scale and will not reach its full potential until it is more widely accessible to all levels of business. Real-world applications are multifaceted and data is siloed, which leads to fragmented AI models. To truly achieve scale, we need a way to consolidate the existing fragmentation. The solution is ‘Multimodal AI’ – the future of deep learning. Jiva has developed next-generation machine learning in AI, helping users to create, modify, enrich, store and deploy scalable multimodal systems. At the core of the company is a team with over a century of experience in creation and commercialisation of AI, data, life sciences, healthcare and software products.
The company’s flagship project, JivaRDX, revolutionises the diagnosis of prostate cancer, which is one of the most prevalent cancers on the planet with an estimated 1.3 million new cases globally every year. Whilst early treatment of the disease yields good outcomes, diagnosis remains problematic.
Far too many patients are having unnecessary, invasive biopsies after their initial scans, which causes massive health economic impacts. As many as 50% of patients suffer complications due to biopsy, whether or not they actually have cancer, and many of them fall into life-threatening illness – a situation that is largely avoidable if diagnosis is more accurate and less subjective at the scanning stage. Combining access to unique data from prominent partners with its AI fusion technology, Jiva has developed a solution that can outperform a human radiologist. The prostate cancer diagnostic product is on track to complete regulatory alignment towards the end of 2021 and commercialise in 2022.
In another project, IDLiver, Jiva is is creating multiple diagnostics for liver disease, taking into account patient record data, socioeconomic statistics, imaging, genetics, biomarkers and more. This is a truly multimodal analytics project, and counts Roche Diagnostics, GE Healthcare, Manchester and Nottingham universities and NHS trusts as partners.
